Oculis announces pricing of USD 100 million oversubscribed offering of shares

Friday, February 14, 2025 @ 2:00 am

Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations in ophthalmology, today announced the pricing of an underwritten offering of 5,000,000 of its ordinary shares, CHF 0.01 nominal value per share, at a price of $20.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses (the “Offering”).

The oversubscribed Offering is expected to close on or about February 18, 2025, subject to satisfaction of customary closing conditions. Before closing, the new shares will be issued out of the Company’s existing capital band (Kapitalband), bringing the total number of registered shares authorized by the Company as per its Articles of Association up to 53,943,700.

Oculis intends to use the net proceeds from the Offering to advance and accelerate its clinical development pipeline, particularly the development of its novel neuroprotective clinical candidate Privosegtor (OCS-05), as well as for working capital and general corporate purposes.

BofA Securities and Leerink Partners are acting as joint bookrunning managers for the Offering. Pareto Securities is acting as lead manager for the Offering. Arctica Finance is acting as financial advisor for the Offering.

You may also be interested in

Celonic: Long-term manufacturing service agreement with LINDIS Biotech

LINDIS Biotech has received an EMA Marketing Authorization for catumaxomab, making it the only drug approved for the specific and cancer-directed treatment of malignant ascites. Celonic Group will manufacture catumaxomab for commercial supply. Catumaxomab will be manufactured at Celonic’s state-of-the-art GMP facility manufacturing facility in Heidelberg, Germany.
February 19, 2025

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

LimmaTech: First patients vaccinated against Staphylococcus aureus

CARB-X awards LimmaTech US$6.5 million to advance clinical development of LBT-SA7 LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participants have been vaccinated in a Phase 1 controlled study of its multivalent vaccine candidate, LBT-SA7. The candidate is designed to prevent skin and soft
February 17, 2025

CELLnTEC joins EU consortium to develop bioprinted liver constructs

European Union (EU) Horizon Europe and Swiss State Secretariat for Education, Research, and Innovation co-funded NEOLIVER Consortium (total €10M award) is set to develop world’s first autologous bioprinted liver designed for clinical use. Coordinated by University of Utrecht, twelve consortium members will develop technologies to establish an automated manufacturing line, vascularize the biopr
February 10, 2025

BioVersys is now publicly listed on the SIX Swiss Exchange

Today, BioVersys (Ticker “BIOV”), a leading Swiss biotech company specializing in novel antibacterial products for serious life-threatening infections, listed its shares at SIX Swiss Exchange. At an opening price of CHF 36.50 per share, the resulting market capitalization of BioVersys was around CHF 216 million.
February 7, 2025

Ariceum: FDA Orphan Drug Designation for radiopharmaceutical cancer therapy

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to 225Ac-SSO110 (satoreotide) for the treatment of patients with Small Cell Lung Cancer (SCLC).
February 6, 2025